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ABSTRACT
Histological chorioamnionitis is associated with significant adverse maternal, perinatal and long-
term outcome. We performed a meta-analysis of 30 observational studies in order to clarify the
association between Histological chorioamnionitis and pulmonary complications, like respiratory
distress syndrome and Bronchopulmonary Dysplasia. Unadjusted data extracted from all studies
showed that Histological chorioamnionitis has no effect on development of RDS (RR 0.93, 95%
CI 1.08–1.67), while it increased the risk of Bronchopulmonary Dysplasia (RR 1.75, 95% CI
1.37–2.23). However, when we restricted the analysis to the studies that adjust for Gestational
Age, in order to exclude the influence of prematurity, we found that HCA reduced the risk of
respiratory distress syndrome (RR 0.57, CI 95% 0.35–0.93) and it did not affect the development
of Bronchopulmonary Dysplasia (RR 0.99, CI 0.76–1.3). Our results confirmed a possible role of
prenatal inflammation on lung maturation. However, further prospective studies with a selected
population are needed, in order to clarify the role of Histological chorioamnionitis in neonatal
pulmonary complications.
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Introduction
Chorioamnionitis (CA) is the inflammatory response to
acute inflammation of the membranes and chorion of
the placenta [1]. It is characterized by microscopic evi-
dence of an inflammation of the membranes, due to
infiltration of polymorphonuclear leukocytes and other
immunocytes, such as macrophages and T-cell [1].
Its frequency is inversely related to gestational age
(GA), ranging from more than 50% at viability to 5%
at term [2]. Therefore, it is strongly related to preterm
delivery, and it can contribute to premature-related
morbidity and mortality.
CA is associated with adverse maternal and peri-
natal outcomes [3]. However, it is extremely challeng-
ing to discriminate the effects of CA its self, from
those of prematurity on neonatal outcomes. Moreover,
the effects of fetal exposure to inflammation in pre-
term newborns are not clear yet and data previously
reported are controversial [4,5].
Previous studies have demonstrated that on one
hand, CA seems to promote lung maturation and to
protect against respiratory distress syndrome (RDS); on
the other hand, this short-term beneficial effect can
contribute to an increased risk of bronchopulmonary
dysplasia (BPD) [1]. Therefore, it has been proposed
that prenatal inflammation can determine the so-
called “early-protection, late-damage” scenario or
Watterberg effect [6].
It has been demonstrated that factors affecting
lung growth and function during fetal life, may have a
lasting impact on lung function later in life [7].
Thus, the aim of this study was to conduct a sys-
tematic review and updated meta-analysis of previous
published observational studies assessing the effect of
histological CA (HCA) on RDS and BPD in preterm
singleton births.
Materials and methods
Research strategy
This review was performed according to a protocol
recommended for systematic review [8]. The research
was conducted using Medline, Embase, Web of
Sciences, Scopus, Ovid and Cochrane Library as elec-
tronic databases. The citations were identified with
the use of a combination of the following text words:
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“histological chorioamnionitis”, “fetal inflammatory
response syndrome”, “funisitis”, “placental infection”,
“placental inflammation”, “respiratory distress syn-
drome”, “bronchopulmonary dysplasia”, “chronic lung
disease”, “prematurity”, “preterm birth” from 2000
through June 2018. Review of articles also included
the abstracts of all references retrieved from
the search.
Study selection
Selection criteria included only observational studies
comparing incidence of RDS and BPD in preterm
births complicated by HCA compared with controls.
Only studies where the diagnosis of CA was confirmed
by histological examination of the placenta were
included. Exclusion criteria were: languages different
from English, abstract conference, inclusion of twin
pregnancies and inclusion of term pregnan-
cies (>37weeks).
Risk of bias assessment
Two reviewers (GS, LDC) independently assessed the
risk of bias of the included studies via the
Methodological Index for Non-Randomized Studies [9].
Seven domains that are related to risk of bias were
assessed in each study [1]: aim (i.e. clearly stated aim)
[2], rate (i.e. inclusion of consecutive patients and
response rate) [3], data (i.e. prospective collection of
data) [4], bias (i.e. unbiased assessment of study end-
points) [5], time (i.e. follow-up time appropriate) [6],
loss (i.e. loss to follow-up) [7], size (i.e. calculation of
the study size) [9].
Review authors’ judgments were categorized as
“low risk”, “high risk” or “unclear risk of bias”.
Discrepancies were resolved by discussion with a third
reviewer (GMM).
Primary outcome
The primary outcome was the incidence of RDS and
BPD in pregnancies complicated by HCA compared
to controls.
Subgroup analysis
To eliminate the effect of prematurity as a confounder,
we performed a subgroup analysis including all the
studies that showed no significant difference in GA
between the HCA-group and the non-HCA group.
Moreover, in order to assess whether the presence of
funisitis or fetal inflammatory response syndrome was
related to a worse respiratory neonatal outcome, we
compared the incidence of RDS and BPD in CA with
and without funisitis.
Statistical analysis
Data analysis was completed independently by two
authors (LS, LDC) using Review Manager v. 5.3 (The
Nordic Cochrane Center, Cochrane Collaboration, 2014,
Copenhagen, Denmark). The completed analyses were
then compared, and any difference was resolved by dis-
cussion. The summary measures were reported as sum-
mary relative risk (RR) with 95% confidence interval (CI)
using the random-effects model of DerSimonian and
Laird. I-squared (Higgins I2) greater than 0% was used
to identify heterogeneity. Potential publication bias was
assessed graphically by using the Funnel Plot.
Data from each eligible study were extracted without
modification of original data onto custom-made data
collection forms. A 2 by two table was assessed for RR.
The meta-analysis was reported following the
Preferred Reporting Item for Systematic Reviews and
Meta-analysis (PRISMA) statement [10].
Results
Description of the included studies
We identified 3741 potentially relevant studies for our
meta-analysis. Figure 1 shows the flow diagram
(PRISMA template) of information derived from review-
ing potentially relevant articles. Thirty observational
studies met our study requirements. Among these, 18
studies [11–28] (5839 patients) reported data about
the relationship between HCA and RDS and 27
[11–14,17,19–40] (6099 patients) reported data about
HCA and BPD.
Funnel plots for a visual inspection of publication
bias are reported in Figure 2.
Studies were published between 2000 and 2015
and they included patients from 1989 to 2011. The
methodological characteristics of all the included stud-
ies are summarized in Table 1.
The overall risk of bias is represented in Figure 3.
All studies had a low risk of bias in “aim” and most
risk in “rate” and in “time”.
Primary outcome
Pooled data showed no statistically significant differ-
ences in the incidence of RDS comparing the HCA-
group with the non-HCA group (RR 0.93, 95% CI
2 L. SARNO ET AL.
1.08–1.67), while the incidence of BPD was signifi-
cantly higher in HCA-group compared to non-HCA
group (RR 1.68, 95% CI 1.19–2.36).
Subgroup analysis
Eight studies were included in the subgroup analysis.
Among these, four studies [11,12,18,20] reported data
about RDS and 7 about BPD [11,12,20,31,34–36].
Pooled data showed that HCA has a protective effect
on the development of RDS (RR 0.57, CI 95%
0.35–0.93), while there is no statistically significant dif-
ference in the development of BPD between HCA and
non-HCA group (RR 0.99, CI 0.76–1.3).
The incidence of BPD and RDS in HCA with or with-
out funisitis or fetal inflammatory response syndrome
was assessed in six [20,24,27–30] and five studies
[16,20,24,27,28], respectively. Pooled data showed that
presence of funisitis or fetal inflammatory response
syndrome does not affect the risk of both BPD (RR
1.16, CI 0.81–1.66) and RDS (RR 0.80, CI 0.25–2.51).
Discussion/conclusion
We performed a meta-analysis of 30 studies to assess
the influence of HCA on pulmonary complications in
preterm births, considering two primary outcomes:
RDS and BPD. The meta-analysis of unadjusted data
extracted from all studies showed that HCA has no
effect on the development of RDS, while it increases
the risk of BPD. When we restrict the analysis to the
studies that adjust for GA, in order to exclude the
influence of prematurity, we found that HCA reduces
the risk of RDS and it does not affect the development
of BPD. No differences in the incidence of BPD and
RDS were found between HCA with and without funi-
sitis or fetal inflammatory response syndrome.
This result confirmed a possible role of prenatal
inflammation on lung maturation. We know that fetal
lungs are very plastic and their development can be
conditioned by endogenous and exogenous factors
[41]. The plausibility of an association between pre-
natal inflammation and lung maturation has been
largely explored in different animal models, even if
they differ in their fetal development, compared to
humans. In preterm lambs, intra-amniotic injection of
lipopolysaccharide increased inflammatory cells in
Figure 2. (a) Funnest plot for the assessment of publication bias: HCA versus non-HCA, outcome RDS; (b) Funnest plot for the
assessment of publication bias: HCA versus non-HCA, outcome BPD.
Figure 1. Study flow diagram.
THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE 3
Ta
bl
e
1.
M
et
ho
do
lo
gi
ca
lc
ha
ra
ct
er
is
tic
s
of
al
lt
he
in
cl
ud
ed
st
ud
ie
s.
Au
th
or
,y
ea
r
Se
tt
in
g
St
ud
y
de
si
gn
Pe
rio
d
In
cl
ud
ed
pa
tie
nt
s
In
cl
us
io
n
cr
ite
ria
D
ef
in
iti
on
of
RD
S
D
ef
in
iti
on
of
BP
D
Ah
n
20
12
[1
1]
Ko
re
a
pr
os
pe
ct
iv
e
20
05
–2
01
0
25
7
(8
9
ve
rs
us
16
8)
al
li
nf
an
ts
<
34
w
ee
ks
re
sp
ira
to
ry
di
st
re
ss
,a
n
in
cr
ea
se
d
ox
yg
en
re
qu
ire
m
en
t
an
d
a
ra
di
ol
og
ic
al
fin
di
ng
co
ns
is
te
nt
w
ith
RD
S
cr
ite
ria
of
th
e
N
at
io
na
lI
ns
tit
ut
e
of
Ch
ild
an
d
H
um
an
D
ev
el
op
m
en
t
Ar
ay
ic
i2
01
4
[1
2]
Tu
rk
ey
re
tr
os
pe
ct
iv
e
20
10
–2
01
1
28
1
(1
45
ve
rs
us
13
6)
al
li
nf
an
ts

32
w
ee
ks
sy
m
pt
om
at
ic
in
fa
nt
s
w
ho
re
qu
ire
d
ve
nt
ila
to
r
su
pp
or
t
fo
r
at
le
as
t
24
h
an
d
ra
di
og
ra
ph
-
ic
al
ly
co
nf
irm
ed
hy
al
in
e
m
em
br
an
e
di
se
as
e
or
a
di
ag
no
si
s
of
re
sp
ira
to
ry
in
su
ffi
ci
en
cy
of
pr
em
at
ur
ity
re
qu
ire
m
en
t
fo
r
su
pp
le
m
en
ta
lo
xy
ge
n
at
36
w
ee
ks
po
st
m
en
st
ru
al
ag
e
Ch
oi
20
08
[2
5]
Ko
re
a
pr
os
pe
ct
iv
e
19
99
–2
00
4
63
(2
3
ve
rs
us
40
)
al
li
nf
an
ts
<
34
w
ee
ks
)
ad
m
itt
ed
to
N
IC
U
w
ith
en
do
tr
ac
he
al
in
tu
ba
tio
n
at
de
liv
er
y
ro
om
,a
nd
ab
se
nc
e
of
m
aj
or
co
ng
en
ita
l
an
om
al
ie
s
N
/A
st
at
e
of
ch
ro
ni
c
ox
yg
en
re
qu
ire
m
en
t
at
36
w
ee
ks
po
st
m
en
st
ru
al
ag
e
pl
us
a
to
ta
lo
xy
ge
n
du
ra
tio
n
of

28
da
ys
w
ith
a
co
ns
is
te
nt
ch
es
t
ra
di
og
ra
ph
ic
fin
di
ng
,w
hi
ch
is
pe
rs
is
te
nt
ha
zy
op
ac
ifi
ca
tio
n
or
a
cy
st
-li
ke
pa
tt
er
n
of
de
ns
ity
an
d
lu
ce
nc
y
Cu
rle
y
20
03
[3
7]
U
K
pr
os
pe
ct
iv
e
N
/A
79
(1
8
ve
rs
us
61
)
in
fa
nt
s
bo
rn
le
ss
th
an
33
w
ee
ks
’g
es
ta
tio
n
an
d
re
qu
ire
d
in
tu
ba
tio
n
an
d
m
ec
ha
ni
ca
lv
en
til
at
io
n
w
ith
in
th
e
fir
st
48
h
of
lif
e
N
/A
ox
yg
en
de
pe
nd
en
ce
at
36
w
ee
ks
’
po
st
co
nc
ep
tio
na
la
ge
to
m
ai
nt
ai
n
ar
te
ria
lo
xy
ge
n
sa
tu
ra
tio
n
gr
ea
te
r
th
an
92
%
by
pu
ls
e
ox
im
et
ry
D
e
Fe
lic
e
20
05
[6
3]
Ita
ly
pr
os
pe
ct
iv
e
N
/A
11
6
(6
7
ve
rs
us
49
)
VL
BW
in
bo
rn
in
fa
nt
s
(G
A:
28
.1
±
2.
82
w
ks
;
BW
:1
00
9
±
31
2
g)
do
cu
m
en
ta
tio
n
of
an
y
3
of
th
e
fo
llo
w
in
g
cr
ite
ria
:(
1)
in
fa
nt
ox
yg
en
re
qu
ire
m
en
t
at
6
h
th
ro
ug
h
24
h
of
lif
e,
(2
)
an
ab
no
rm
al
ch
es
t
ra
di
og
ra
ph
th
at
w
as
co
ns
is
te
nt
w
ith
RD
S
w
ith
in
th
e
fir
st
24
h
of
lif
e,
an
d
(3
)
th
e
ne
ed
fo
r
su
rf
ac
ta
nt
ox
yg
en
re
qu
ire
m
en
t
at
28
da
ys
,a
nd
ch
ro
ni
c
lu
ng
di
se
as
e
w
as
de
fin
ed
as
ox
yg
en
re
qu
ire
m
en
t
at
36
w
ee
ks
of
lif
e
D
em
ps
ey
20
05
[1
4]
Ca
na
da
re
tr
os
pe
ct
iv
e
19
89
–1
99
9
34
2
(1
40
ve
rs
us
20
2)
ne
w
bo
rn
<
30
w
ks
co
m
bi
na
tio
n
of
th
re
e
of
th
e
fo
llo
w
in
g:
cl
in
ic
al
si
gn
s,
ox
yg
en
ne
ed
gr
ea
te
r
th
an
30
%
fr
om
12
to
72
h,
ne
ed
fo
r
as
si
st
ed
ve
nt
ila
tio
n
(c
on
tin
uo
us
po
si
tiv
e
ai
rw
ay
pr
es
su
re
or
m
ec
ha
ni
ca
l
ve
nt
ila
tio
n)
,a
nd
ty
pi
ca
lc
he
st
X-
ra
y
ap
pe
ar
an
ce
.
N
/A
D
es
sa
rd
o
20
12
[2
9]
Cr
oa
tia
pr
os
pe
ct
iv
e
20
03
–2
00
7
18
9
(6
9
ve
rs
us
12
0)
al
ln
eo
na
te
s
32
w
ee
ks
ne
ed
fo
ro
xy
ge
n
or
m
ec
ha
ni
ca
lv
en
til
at
or
y
su
pp
or
t
at
2
da
ys
of
ag
e
N
/A
El
im
ia
n
20
00
[1
5]
U
SA
re
tr
os
pe
ct
iv
e
19
90
–1
99
7
12
60
(5
27
ve
rs
us
73
3)
ne
w
bo
rn
s
w
ei
gh
ed
be
tw
ee
n
50
0
an
d
17
50
g
ne
ed
fo
r
m
ec
ha
ni
ca
lv
en
til
at
io
n
an
d
ox
yg
en
fo
r
at
le
as
t
48
h,
an
d
ra
di
ol
og
ic
ch
es
t
fin
di
ng
s
N
/A
H
ol
cr
of
t
20
04
[1
6]
U
SA
re
tr
os
pe
ct
iv
e
19
99
–2
00
2
35
4
(1
46
ve
rs
us
20
8)
al
li
nf
an
ts
ad
m
itt
ed
to
N
IC
U
be
tw
ee
n
23
an
d
30
w
ks
N
/A
N
/A
H
on
m
a
20
07
[3
8]
Ja
pa
n
re
tr
os
pe
ct
iv
e
19
97
–2
00
1
10
7
(3
9
ve
rs
us
66
)
al
li
nf
an
ts

32
w
ee
ks
ad
m
itt
ed
to
N
IC
U
N
/A
th
e
pr
es
en
ce
of
pe
rs
is
te
nt
re
sp
ira
to
ry
di
st
re
ss
an
d
a
ha
zy
or
em
ph
ys
em
at
ou
s
an
d
fib
ro
us
ap
pe
ar
an
ce
up
on
X-
ra
y
an
d
th
e
ne
ce
ss
ity
fo
r
ox
yg
en
at
28
da
ys
of
ag
e
(c
on
tin
ue
d)
4 L. SARNO ET AL.
Ta
bl
e
1.
Co
nt
in
ue
d.
Au
th
or
,y
ea
r
Se
tt
in
g
St
ud
y
de
si
gn
Pe
rio
d
In
cl
ud
ed
pa
tie
nt
s
In
cl
us
io
n
cr
ite
ria
D
ef
in
iti
on
of
RD
S
D
ef
in
iti
on
of
BP
D
H
ue
tz
20
16
[1
7]
Fr
an
ce
pr
os
pe
ct
iv
e
an
d
re
tr
os
pe
ct
iv
e
20
08
–2
01
1
27
6
(5
7
ve
rs
us
21
9)
al
ls
in
gl
et
on
in
fa
nt
s
bo
rn
be
tw
ee
n
24
þ
0
an
d
33
þ
6
w
ks
N
/A
du
ra
tio
n
of
ve
nt
ila
tio
n
an
d/
or
CP
Ap

28
da
ys
in
al
iv
e
ch
ild
re
n
at
>
36
G
A.
Ke
nt
20
04
[3
0]
Au
st
ra
lia
pr
os
pe
ct
iv
e
19
96
–2
00
1
24
1
(8
0
ve
rs
us
16
1)
ne
w
bo
rn
s<
30
co
m
pl
et
ed
w
ee
ks
ge
st
at
io
n
(m
ea
n
ge
st
at
io
na
l
ag
e
¼
27
.7
w
ee
ks
an
d
m
ea
n
bi
rt
hw
ei
gh
t¼
10
89
g)
N
/A
de
at
h
du
e
to
re
sp
ira
to
ry
fa
ilu
re
or
an
y
ox
yg
en
re
qu
ire
m
en
t
at
36
w
ee
ks
po
st
m
en
st
ru
al
ag
e
Ki
rc
hn
er
20
07
[3
9]
Au
st
ria
re
tr
os
pe
ct
iv
e
19
97
–2
00
1
44
(1
5
ve
rs
us
29
)
pr
et
er
m
la
bo
r
or
pr
et
er
m
pr
em
at
ur
e
ru
pt
ur
e
of
m
em
br
an
es
be
tw
ee
n
24
an
d
32
w
ee
ks
N
/A
ox
yg
en
de
pe
nd
en
ce
at
36
w
ee
ks
of
ge
st
at
io
n
in
or
de
r
to
m
ai
nt
ai
n
a
pe
rc
ut
an
eo
us
ox
yg
en
sa
tu
ra
tio
n
of
m
or
e
th
an
88
%
Ko
su
ge
20
00
[1
8]
Ja
pa
n
re
tr
os
pe
ct
iv
e
19
93
–1
99
7
81
(4
4
ve
rs
us
37
)
si
ng
le
to
n
ne
w
bo
rn
s
23
an
d
<
32
w
ee
ks
ch
es
t
X-
ra
y
fin
di
ng
s
so
on
af
te
r
bi
rt
h
N
/A
Le
e,
20
13
[1
9]
Re
pu
bl
ic
of
Ko
re
a
re
tr
os
pe
ct
iv
e
19
98
–2
00
9
24
4
(5
8
ve
rs
us
18
6)
si
ng
le
to
n
liv
e
pr
et
er
m
ne
w
bo
rn
s
at
34
–3
6
6/
7
w
ee
k
co
m
bi
na
tio
n
of
th
re
e
of
th
e
fo
llo
w
in
g:
cl
in
ic
al
si
gn
s,
ox
yg
en
re
qu
ire
m
en
t>
30
%
fr
om
12
to
72
h,
ne
ed
fo
r
as
si
st
ed
ve
nt
ila
tio
n
(c
on
tin
uo
us
po
si
tiv
e
ai
rw
ay
pr
es
su
re
or
m
ec
ha
ni
ca
lv
en
til
at
io
n)
,a
nd
ty
pi
ca
l
ch
es
t
X-
ra
y
ap
pe
ar
an
ce
ox
yg
en
re
qu
ire
m
en
t
at
36
w
ee
ks
of
co
rr
ec
te
d
G
A
Li
u
20
14
[2
0]
Ch
in
a
pr
os
pe
ct
iv
e
20
08
–2
01
0
21
6
(1
04
ve
rs
us
11
2)
si
ng
le
to
n,
al
iv
e,
an
d
bo
rn
<
34
w
ee
ks
;n
o
m
ul
tip
le
-g
es
ta
tio
n
pr
eg
na
nc
ie
s
an
d
no
m
aj
or
bi
rt
h
de
fe
ct
s
pr
es
en
ce
of
re
sp
ira
to
ry
sy
m
pt
om
s
su
ch
as
gr
un
tin
g
an
d
ch
es
t
re
tr
ac
tio
n,
ty
pi
ca
l
ch
es
t
ra
di
og
ra
ph
fin
di
ng
s,
an
d/
or
tr
ea
tm
en
t
w
ith
su
rf
ac
ta
nt
an
d
th
e
ne
ed
fo
r
as
si
st
ed
ve
nt
ila
tio
n
(in
cl
ud
in
g
na
sa
lc
on
tin
uo
us
po
si
tiv
e
ai
rw
ay
pr
es
su
re
an
d
m
ec
ha
ni
ca
lv
en
til
at
io
n)
su
pp
le
m
en
ta
lo
xy
ge
n
de
pe
nd
en
cy
at
36
w
ee
ks
of
co
rr
ec
te
d
G
A
N
as
ef
20
13
[3
1]
Ca
na
da
re
tr
os
pe
ct
iv
e
20
07
–2
00
8
24
1
(9
5
ve
rs
us
14
6)
ne
w
bo
rn
s<
30
w
ee
ks
N
/A
ox
yg
en
re
qu
ire
m
en
t
at
36
w
ee
ks
of
co
rr
ec
te
d
ge
st
at
io
na
la
ge
N
at
ar
aj
an
20
08
[2
6]
U
SA
pr
os
pe
ct
iv
e
N
/A
48
(2
2
ve
rs
us
26
)
ne
w
bo
rn
s
w
ith
bi
rt
h
w
ei
gh
ts
be
tw
ee
n
50
1
an
d
15
00
g
ne
ed
fo
r
m
ec
ha
ni
ca
lv
en
til
at
io
n
an
d
ox
yg
en
fo
r
at
le
as
t
48
h,
an
d
ra
di
ol
og
ic
ch
es
t
fin
di
ng
s
ox
yg
en
ne
ed
at
36
w
ee
ks
’
po
st
m
en
st
ru
al
ag
e
N
is
hi
m
ak
i2
00
3
[4
0]
Ja
pa
n
re
tr
os
pe
ct
iv
e
20
00
–2
00
2
69
(3
8
ve
rs
us
31
)
ge
st
at
io
na
la
ge
at
bi
rt
h

32
w
ee
ks
,
sp
on
ta
ne
ou
sl
y
vo
id
ed
ur
in
e
sa
m
pl
es
ob
ta
in
ed
us
in
g
ur
in
e
ba
gs
be
fo
re
48
h
of
ag
e,
di
ag
no
si
s
of
CL
D
af
te
r
28
da
ys
of
su
rv
iv
al
,
an
d
ab
se
nc
e
of
m
aj
or
in
tr
av
en
tr
ic
ul
ar
N
/A
ox
yg
en
re
qu
ire
m
en
t
fo
r
28
da
ys
of
ag
e
or
lo
ng
er
to
m
ai
nt
ai
n
a
Pa
O
2
>
50
m
m
H
g
or
an
ar
te
ria
l
ox
yg
en
sa
tu
ra
tio
n
>
90
%
,w
ith
sy
m
pt
om
s
of
pe
rs
is
te
nt
re
sp
ira
to
ry
di
st
re
ss
(t
ac
hy
pn
ea
,i
nt
er
co
st
al
an
d
su
bc
os
ta
lr
et
ra
ct
io
n)
an
d
an
ab
no
rm
al
ch
es
t
ra
di
og
ra
ph
(a
ha
zy
or
em
ph
ys
em
at
ou
s
an
d
fib
ro
us
ap
pe
ar
an
ce
)
(c
on
tin
ue
d)
THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE 5
Ta
bl
e
1.
Co
nt
in
ue
d.
Au
th
or
,y
ea
r
Se
tt
in
g
St
ud
y
de
si
gn
Pe
rio
d
In
cl
ud
ed
pa
tie
nt
s
In
cl
us
io
n
cr
ite
ria
D
ef
in
iti
on
of
RD
S
D
ef
in
iti
on
of
BP
D
he
m
or
rh
ag
e
(g
ra
de
s
III
an
d
IV
),
co
ng
en
ita
la
no
m
al
ie
s,
an
d
ea
rly
-o
ns
et
se
ps
is
on
ad
m
is
si
on
O
gu
ny
em
i2
00
3
[2
1]
U
SA
re
tr
os
pe
ct
iv
e
19
92
–2
00
0
77
4
(2
54
ve
rs
us
52
0)
ne
w
bo
rn
s
24
–3
2
w
ee
ks
N
/A
su
pp
le
m
en
ta
lo
xy
ge
n
at
36
w
ee
ks
O
hy
am
a
20
02
[2
7]
Ja
pa
n
re
tr
os
pe
ct
iv
e
19
93
–1
99
6
27
6
(5
7
ve
rs
us
21
9)
al
ls
in
gl
et
on
in
fa
nt
s
bo
rn
23
–3
2
w
ee
ks
an
d
ad
m
itt
ed
to
N
IC
U
re
su
lt
of
st
ab
le
m
ic
ro
bu
bb
le
ra
tin
g
of
th
e
ga
st
ric
as
pi
ra
te
s
an
d
re
sp
on
se
to
th
e
se
m
is
yn
th
es
iz
ed
su
rf
ac
ta
nt
,i
n
ad
di
tio
n
to
cl
in
ic
al
si
gn
s
an
d
ch
es
t
X-
ra
y
fin
di
ng
s
ox
yg
en
re
qu
ire
m
en
t
gr
ea
te
r
th
an
th
at
ob
ta
in
ab
le
in
ro
om
ai
r
at
28
da
ys
af
te
r
bi
rt
h,
w
ith
sy
m
pt
om
s
of
pe
rs
is
te
nt
re
sp
ira
to
ry
di
st
re
ss
an
d
a
ha
zy
or
em
ph
ys
em
at
ou
s
an
d
fib
ro
us
ap
pe
ar
an
ce
on
ch
es
t
X-
ra
y
Pe
rr
on
e
20
12
[3
2]
Ita
ly
re
tr
os
pe
ct
iv
e
20
08
–2
01
1
65
(4
1
ve
rs
us
24
)
si
ng
le
to
n
ne
w
bo
rn
s
23
–3
1
w
ee
ks
N
/A
ox
yg
en
re
qu
ire
m
en
t
an
d
th
e
pr
es
en
ce
of
ra
di
og
ra
ph
ic
ab
no
rm
al
iti
es
at
36
w
ee
ks
Po
la
m
20
05
[3
3]
U
SA
re
tr
os
pe
ct
iv
e
19
97
–2
00
0
17
7
(1
02
ve
rs
us
75
)
VL
BL
W
in
fa
nt
s
fr
ee
of
m
aj
or
m
al
fo
rm
at
io
ns
,
ad
m
itt
ed
to
N
IC
U
w
ith
a
ge
st
at
io
na
l
ag
e
of
22
–2
9
w
ee
ks
N
/A
ox
yg
en
de
pe
nd
en
t
be
yo
nd
28
da
ys
af
te
r
bi
rt
h
Pr
en
de
rg
as
t
20
11
[3
4]
U
K
pr
os
pe
ct
iv
e
N
/A
12
0
(4
1
ve
rs
us
79
)
si
ng
le
to
n
ne
w
bo
rn
s
<
32
w
ee
ks
N
/A
ox
yg
en
de
pe
nd
en
t
be
yo
nd
28
da
ys
af
te
r
bi
rt
h
Ri
ch
ar
ds
on
20
06
[2
8]
Ca
na
da
pr
os
pe
ct
iv
e
19
93
–2
00
3
66
0
(2
92
ve
rs
us
36
8)
al
ls
in
gl
et
on
in
fa
nt
s
bo
rn
af
te
r
25
co
m
pl
et
ed
w
ee
ks
an
d
be
fo
re
34
co
m
pl
et
ed
w
ee
ks
;n
o
m
aj
or
an
om
al
ie
s;
ei
th
er
sp
on
ta
ne
ou
s
on
se
t
of
la
bo
r
or
de
liv
er
ed
fo
r
su
sp
ec
te
d
ch
or
io
am
ni
on
iti
s;
av
ai
la
bi
lit
y
of
pl
ac
en
ta
lp
at
ho
lo
gy
N
/A
ox
yg
en
ne
ed
at
36
w
ee
ks
’
po
st
m
en
st
ru
al
ag
e
Sc
hl
ap
ba
ch
20
10
[3
5]
Sw
itz
er
la
nd
re
tr
os
pe
ct
iv
e
20
02
–2
00
5
66
(3
3
ve
rs
us
33
)
si
ng
le
to
n
ne
w
bo
rn
s
25
–3
2
þ
6
w
ee
ks
N
/A
re
qu
ire
m
en
t
fo
r
ad
di
tio
na
lo
xy
ge
n
at
36
w
ee
ks
Se
lig
a-
Si
w
ec
ka
20
13
[2
2]
Po
la
nd
pr
os
pe
ct
iv
e
20
05
–2
00
7
38
3
(1
41
ve
rs
us
24
2)
ne
w
bo
rn
s<
32
w
ee
ks
(2
2
1/
7–
31
6/
7
w
ee
k)
of
ge
st
at
io
n;
in
bo
rn
in
fa
nt
s;
pl
ac
en
ta
l
pa
th
ol
og
y
av
ai
la
bl
e;
no
kn
ow
n
co
ng
en
ita
l
m
al
fo
rm
at
io
ns
;
pa
re
nt
al
/c
ar
er
co
ns
en
t
ty
pi
ca
lc
he
st
ra
di
og
ra
ph
w
ith
in
th
e
fir
st
24
h
ox
yg
en
de
pe
nd
en
cy
at
36
w
ee
ks
(c
on
tin
ue
d)
6 L. SARNO ET AL.
bronchoalveolar lavage and resulted in increased lung
maturation, measured as increased airway surfactant
and improved lung gas volumes [42]. Following
exposure to intraamniotic lipopolysaccharide, fetal
sheep developed lung inflammation, improving
maturation and mechanical properties of the lung.
Moreover, interleukin 1a, a proinflammatory cytokine,
has been reported to increase mRNA transcription of
surfactant proteins and surfactant lipids in fetal rab-
bit [43].
Our study did not confirm the role of HCA in the
development of BPD. The paradoxical effect previously
reported in clinical studies can be related to con-
founders, like prematurity or the use of mechanical
ventilation. Moreover, the histological evidence of fetal
damage does not seem to improve or worsen respira-
tory outcome, as reported also in another studies that
we could not include in our subanalysis due to the
fact that data were not shown, since they were non-
statistically significant [34].
Hartling et al. [44] included a larger number of
studies in their meta-analysis compared to ours (59
vs. 30). Differently from them, we decided to include
only cases of HCA and we excluded the studies
reporting data about clinical CA [45–57], because it
is not always confirmed by placental histology; fur-
thermore, it has been established that the histo-
logical definition of CA reflects antenatal
inflammatory exposure better than the clinical one
[58]. Moreover, we excluded studies published before
2000 [6,59,60], in order to limit bias related to pos-
sible different pediatric approaches to these compli-
cations. Finally, we did not include studies
considering also twin pregnancies [61].
As reported in Table 1, the definition of RDS and
BPD was extremely different in the included studies
and data about the severity of these conditions, mech-
anical ventilation, use of surfactant and oxygen sup-
plementation are reported only in few studies, making
very difficult the possibility to analyze the severity of
the reported pulmonary complications and to evaluate
secondary outcomes. This is particularly true for BPD,
due to the complexity of its pathogenesis that cannot
be captured by the clinical definitions of BPD [62].
Moreover, lack of adjustment for possible confounders,
can explain the high degree of heterogeneity
observed across studies in the unadjusted analysis.
However, the heterogeneity was consistently lower in
the subgroup analysis.
Further prospective studies with a selected popula-
tion are needed, in order to clarify the role of HCA in
neonatal pulmonary complications.Ta
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